CWM
TEVA icon

Catamount Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Catamount Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,000
Closed -$66K – 201
2017
Q2 		$66K Hold
2,000
– – 0.04% 78
2017
Q1 		$64K Hold
2,000
– – 0.04% 73
2016
Q4 		$73K Sell
2,000
-4,225
-68% -$169K 0.06% 54
2016
Q3 		$282K Sell
6,225
-13,400
-68% -$699K 0.24% 30
2016
Q2 		$986K Buy
19,625
+7,400
+61% +$394K 1.14% 13
2016
Q1 		$654K Buy
12,225
+1,500
+14% +$88K 0.76% 17
2015
Q4 		$704K Buy
10,725
+9,025
+531% +$558K 0.64% 20
2015
Q3 		$96K Buy
+1,700
New +$110K 0.1% 32

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Catamount Wealth Management's TEVA Position: Q3 2017 in Review

Catamount Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 2,000 shares — an estimated $66K sold.

Catamount Wealth Management first reported a position in TEVA in Q3 2015 and held it in 8 quarters. The position peaked at $986K in Q2 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Catamount Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Catamount Wealth Management sold 2,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $66K.
  • Catamount Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 8 quarters.
  • Catamount Wealth Management's Teva Pharmaceuticals position peaked at $986K in Q2 2016.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Catamount Wealth Management's 13F filing for Q3 2017, filed 13 Nov 2017.